Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on June 14, 2018. The report details corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from six to eight directors.
- New Appointment: Mr. Gregory J. Divis was appointed as a Class III director to fill one of the newly created vacancies.
- Term: Mr. Divis will serve until the 2021 annual meeting of stockholders or until his successor is elected and qualified.
Management Commentary and Background
The Board concluded that Mr. Divis is qualified to serve due to his extensive experience in the pharmaceutical industry. His background includes:
- Current Chief Operating Officer of Avadel Pharmaceuticals plc (joined 2017).
- Former Executive-in-Residence and Operating Partner at Linden Capital Partners.
- Former President and CEO of Lumara Health, Inc., where he led a successful turnaround and sale to AMAG Pharmaceuticals, Inc.
- Previous roles at Sanofi-Aventis and Schering-Plough Corporation.
- Current board member of Mobius Therapeutics and former board member of Tolero Pharmaceuticals.
A press release regarding this appointment was issued on June 18, 2018, and is filed as Exhibit 99.1.
Investor Verification Checklist
- Verify the official press release dated June 18, 2018 (Exhibit 99.1) for additional details on the appointment.
- Confirm the total number of board seats and the status of the second newly created vacancy.
- Review Mr. Divis's potential conflicts of interest given his current role at Avadel Pharmaceuticals plc.
- Check subsequent filings for the election of the second new director to complete the board expansion.